- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06630234
Um protocolo mestre para avaliar DCC-3009 em tumor estromal gastrointestinal (GIST)
Um protocolo mestre para o estudo multicoorte, aberto, de fase 1/2 de DCC-3009 em participantes com tumor estromal gastrointestinal (GIST)
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 3 parts: Part 1 (Dose Escalation), Part 2 (Dose Expansion), and Part 3 (Food Effect [FE] and Drug-Drug Interaction [DDI]). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Clinical Team
- Número de telefone: 888-724-3274
- E-mail: clinicaltrials@deciphera.com
Locais de estudo
-
-
Arizona
-
Scottsdate, Arizona, Estados Unidos, 85258
- Recrutamento
- HonorHealth
-
Contato:
- Program Management
- E-mail: hriprograms@honorhealth.com
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- Recrutamento
- UC San Diego Moores Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- University of Colorado Anschutz Medical Campus
-
Contato:
- Steven Sares
- Número de telefone: 303-724-9889
- E-mail: steven.sares@cuanschutz.edu
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Recrutamento
- Mayo Clinic Florida
-
Contato:
- Caroline Teeter
- Número de telefone: 904-953-5141
- E-mail: teeter.caroline@mayo.edu
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami - Sylvester Comprehensive Cancer Center
-
Contato:
- Leah Anton, ARNP
- Número de telefone: 305-243-2529
- E-mail: lxa712@med.miami.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Dana Farber Cancer Institute
-
Contato:
- Research Nurse
- Número de telefone: 617-632-5204
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Recrutamento
- START Midwest
-
Contato:
- Hope Team
- E-mail: hopeteam@startresearch.com
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic Rochester
-
Contato:
- Jordan Meyers
- Número de telefone: 507-284-2030
- E-mail: Meyers.jordan@mayo.edu
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
Contato:
- Ping Chi, MD
- Número de telefone: 646-888-4166
- E-mail: chip@mskcc.org
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University-Ingram Cancer Center
-
Contato:
- Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)
- Número de telefone: 800-811-8480
- E-mail: CTIP@VUMC.ORG
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
Module A:
- Have at least 1 measurable lesion as defined by mRECIST, v1.1
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
- Adequate organ function, bone marrow function, and electrolytes
- All participants agree to comply with the contraception requirements
- Have a life expectancy of more than 3 months
Module A Part 1 (Escalation) and Part 3 (FE and DDI):
-Any participant with histologically or cytologically confirmed advanced/unresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting
Module A Part 2 (Expansion):
-Any participant with histologically or cytologically confirmed advanced or metastatic GIST with documented KIT or PDGFRA mutation
Module A Part 3 (FE and DDI):
-Able to consume a high-fat meal
Key Exclusion Criteria:
- Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug
- Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer
- Has known active central nervous system (CNS) metastases or an active primary CNS cancer
- History or presence of clinically relevant cardiovascular abnormalities
- Major surgery within 28 days of the first dose of study drug
- Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug
- Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug
- Known allergy or hypersensitivity to any component of the study drug
- Malabsorption syndrome or other illness that could affect oral absorption
- Any other clinically significant comorbidities
Module A Part 3 (FE and DDI):
- Allergy or hypersensitivity to rabeprazole or any of its excipients
- Unable or unwilling to adhere to overnight fasting of 10 hours
Other protocol-specified inclusion and exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: DCC-3009 Module A
Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation, Part 2 dose expansion, and Part 3 FE and DDI. Participants in Part 3 will also receive rabeprazole. |
Administered orally Administered orally (Part 3 only) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)
Prazo: Cycle 1 (28 Days)
|
DLTs assessed for each dose level. |
Cycle 1 (28 Days)
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)
Prazo: Cycle 1 (28 Days)
|
Cycle 1 (28 Days)
|
|
|
Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)
Prazo: Cycle 1 (28 Days)
|
Cycle 1 (28 Days)
|
|
|
Objective Response Rate (ORR) (Part 2 Expansion)
Prazo: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST), v1.1. |
Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
|
Pharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR) (Part 1 Escalation and Part 3 FE and DDI)
Prazo: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on mRECIST, v1.1. |
Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
|
Disease Control Rate (DCR)
Prazo: Weeks 16, 24, 32
|
DCR is the proportion of participants who achieve CR, PR, or stable disease at the specified time point per mRECIST, v1.1. |
Weeks 16, 24, 32
|
|
Duration of Response (DOR)
Prazo: First Recorded CR or PR until PD or Death (Estimated up to 24 months)
|
DOR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the disease progression is objectively documented or death, whichever occurs first. |
First Recorded CR or PR until PD or Death (Estimated up to 24 months)
|
|
Time to Response (TTR)
Prazo: Baseline to First Recorded CR or PR (Estimated up to 24 months)
|
TTR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per mRECIST, v1.1. |
Baseline to First Recorded CR or PR (Estimated up to 24 months)
|
|
Progression-Free Survival (PFS)
Prazo: Initiation of Treatment to PD or Death (Estimated up to 24 months)
|
PFS is the time from initiation of treatment until documented disease progression per mRECIST, v1.1, or death, whichever occurs first. |
Initiation of Treatment to PD or Death (Estimated up to 24 months)
|
|
Overall Survival (OS)
Prazo: Initiation of Treatment to Death from Any Cause (Estimated up to 24 months)
|
OS is the time from initiation of treatment to the date of death from any cause. |
Initiation of Treatment to Death from Any Cause (Estimated up to 24 months)
|
|
PK: Tmax (Part 1 Escalation and Part 2 Expansion)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Cmax (Part 1 Escalation and Part 2 Expansion)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Ctrough (Part 1 Escalation and Part 2 Expansion)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: AUC (Part 1 Escalation and Part 2 Expansion)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
Number of Participants with TEAEs or SAEs (Part 2 Expansion and Part 3 FE and DDI)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 2 Expansion and Part 3 FE and DDI)
Prazo: Estimated up to 24 months
|
Estimated up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Team, Deciphera Pharmaceuticals, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias de Tecidos Conjuntivos e Moles
- Neoplasias do Tecido Conjuntivo
- Tumores Estromais Gastrointestinais
- 2-piridinilmetilsulfinilbenzimidazóis
- Sulfóxidos
- Compostos de enxofre
- Produtos químicos orgânicos
- Piridinas
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Benzimidazóis
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Rabeprazol
Outros números de identificação do estudo
- DCC-3009-01-001
- 2026-525379-20-00 (Ctis)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .